Japanese flu vaccine makers jack up price ahead of flu season; Supreme Court won't hear challenge to NY public schools vaccination requirement;

> Four Japanese flu vaccine makers have hiked their prices by 50% just ahead of the flu season. Story

> The Supreme Court will not hear a challenge to New York state's requirement that children get vaccinated before starting public school. Article

> Abivax is evaluating HeberNavasc, the new Cuban vaccine for the treatment of chronic hepatitis B in 8 countries. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.